Key facts
- It has raised $52.0M across 2 recorded rounds; the latest was Early Stage VC ($40.0M) in Jul 2024.
- Notable investors include Khosla Ventures, AWS Startups, DCVC, Catalio Capital Management, Polaris Partners — 25 tracked in total.
- Noetik has filed 2 Form Ds with the SEC since 2022, most recently Aug 2024 ($40.0M sold to 20 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 25 names
- ·Watchlist + deal alerts for Noetik
Funding rounds
2 roundsAbout Noetik
Operator of an artificial intelligence native drug discovery company intended to discover and develop cancer immunotherapies. The company's platform uses machine learning to identify new targets and design new treatments by harnessing the potential of self-supervised learning and human multimodal data to discover better precision immunotherapies, enabling clients to boost the development of more effective and personalized cancer therapies.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2022
- Employees
- 40
- Website
- noetik.ai/
- Ownership
- Privately Held (backing)
Noetik doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Noetik shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Noetik in its N-PORT filings yet. We sweep new filings monthly.